Liver Cancer News and Research

RSS
Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
Liver cancer patients gain clarity on surgery options through precision medicine tool

Liver cancer patients gain clarity on surgery options through precision medicine tool

Environmental factors significantly impact gene expression through epigenetic modifications

Environmental factors significantly impact gene expression through epigenetic modifications

Study reveals gaps in hepatitis C treatment among reproductive-aged women

Study reveals gaps in hepatitis C treatment among reproductive-aged women

Study links obesity and diabetes to higher recurrence rates in liver cancer

Study links obesity and diabetes to higher recurrence rates in liver cancer

Novel lipid nanoparticles enhance tissue-specific drug delivery

Novel lipid nanoparticles enhance tissue-specific drug delivery

Traditional Chinese medicine shows potential in cancer treatment

Traditional Chinese medicine shows potential in cancer treatment

Regulating iron overload: Liraglutide's potential benefits

Regulating iron overload: Liraglutide's potential benefits

Study sheds light on mechanisms behind liver fibrosis and potential therapies

Study sheds light on mechanisms behind liver fibrosis and potential therapies

PPARs and PROTACs: A new strategy in cancer therapeutics

PPARs and PROTACs: A new strategy in cancer therapeutics

A promising new therapeutic target for MASLD identified

A promising new therapeutic target for MASLD identified

Scientists discover key to activating natural killer cells against cancer

Scientists discover key to activating natural killer cells against cancer

Researchers demonstrate a new method to combat pancreatic cancer

Researchers demonstrate a new method to combat pancreatic cancer

New insights into macrophages' role in MASH and liver fibrosis

New insights into macrophages' role in MASH and liver fibrosis

Breakthrough treatment reduces liver fibrosis in Hepatitis C patients

Breakthrough treatment reduces liver fibrosis in Hepatitis C patients

SwRI develops a unique technology to screen new DNA-targeting therapeutics

SwRI develops a unique technology to screen new DNA-targeting therapeutics

X-ray irradiation emerges as a new tool to combat aflatoxin-contaminated corn

X-ray irradiation emerges as a new tool to combat aflatoxin-contaminated corn

Neoadjuvant immunotherapy yields comparable outcomes in high-risk liver cancer surgery

Neoadjuvant immunotherapy yields comparable outcomes in high-risk liver cancer surgery

Liver stiffness becomes crucial indicator for post-treatment hepatitis C risk assessment

Liver stiffness becomes crucial indicator for post-treatment hepatitis C risk assessment

The interplay of liver cancer stem cells and immune cells in tumor microenvironment

The interplay of liver cancer stem cells and immune cells in tumor microenvironment

Rising cancer rates in younger generations signal urgent need for early-life prevention strategies

Rising cancer rates in younger generations signal urgent need for early-life prevention strategies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.